quant-phMar 18, 2026

The Convergence Frontier: Integrating Machine Learning and High Performance Quantum Computing for Next-Generation Drug Discovery

Authors: Narjes Ansari, César Feniou, Nicolaï Gouraud, Daniele Loco, Siwar Badreddine, Baptiste Claudon, Félix Aviat, Marharyta Blazhynska, 

Organizations: Qubit Pharmaceuticals, Advanced Research Department, 75014 Paris, France · Qubit Pharmaceuticals Inc, Advanced Research Department, Chicago, IL, USA · Sorbonne Université, Laboratoire de Chimie Théorique, UMR 7616 CNRS, 75005 Paris, France

Abstract

Integrating quantum mechanics into drug discovery marks a decisive shift from empirical trial-and-error toward quantitative precision. However, the prohibitive cost of ab initio molecular dynamics has historically forced a compromise between chemical accuracy and computational scalability. This paper identifies the convergence of High-Performance Computing (HPC), Machine Learning (ML), and Quantum Computing (QC) as the definitive solution to this bottleneck. While ML foundation models, such as FeNNix-Bio1, enable quantum-accurate simulations, they remain tethered to the inherent limits of classical data generation. We detail how High-Performance Quantum Computing (HPQC), utilizing hybrid QPU-GPU architectures, will serve as the ultimate accelerator for quantum chemistry data. By leveraging Hilbert space mapping, these systems can achieve true chemical accuracy while bypassing the heuristics of classical approximations. We show how this tripartite convergence optimizes the drug discovery pipeline, spanning from initial system preparation to ML-driven, high-fidelity simulations. Finally, we position quantum-enhanced sampling as the beyond GPU frontier for modeling reactive cellular systems and pioneering next-generation materials.

Figures & tables

Explore similar work

Jul 13, 2026

Q2SAR\mathtt{Q^2SAR}: overcoming classical bottlenecks in drug discovery via quantum multiple kernel learning

Quantitative Structure-Activity Relationship (QSAR\mathtt{QSAR}) modeling is a foundational computational methodology in early-stage drug discovery, heavily relied upon for predicting compound toxicity, bioavailability, and therapeutic potential. However, classical methods often struggle to effectively map the highly complex, non-linear, and high-dimensional interactions inherent in molecular data, leading to reduced predictive accuracy and costly late-stage clinical failures. In this paper, we present a Quantum Multiple Kernel Learning (QMKL\mathtt{QMKL}) framework, dubbed Next-Gen Q2SAR\mathtt{Q^2SAR}, that leverages Quantum Support Vector Machines (QSVMs\mathtt{QSVMs}) to overcome these classical limitations. By encoding molecular descriptors into exponentially large quantum Hilbert spaces, our approach substantially enhances the expressiveness of non-linear modeling. Benchmarking our quantum-enhanced framework on a dataset targeting the DYRK1A\mathtt{DYRK1A} kinase (a critical target for Alzheimer's disease), the QMKL\mathtt{QMKL}-SVM\mathtt{SVM} achieves an impressive Area Under the Curve (AUC\mathtt{AUC}) score of 0.87500.8750, significantly outperforming classical state-of-the-art Gradient Boosting models (AUC=0.8037\mathtt{AUC} = 0.8037). Furthermore, we establish a theoretical and empirical pathway toward resolving classical data bottlenecks through projected quantum kernels (PQK\mathtt{PQK}) and measurement accelerators. As quantum computing architecture matures, this framework paves the way for autonomous cognitive architectures and self-improving drug discovery pipelines, promising to unlock deeper insights across vast chemical spaces and to accelerate the development of life-saving therapeutics.
Jun 29, 2026

Bridging the NISQ and Fault-Tolerant Regimes: Generative-ML-Assisted Quantum Selected CI for Molecular Simulations

Calculation of binding energies for protein-ligand molecular systems requires accurate treatment of the electronic structure, a quantum chemistry problem that scales exponentially on classical hardware, while current quantum hardware remains too noisy for the required circuit depths. This report presents a hybrid quantum-classical workflow performed on the Fujitsu FX700 ideal state-vector simulator using QARP that addresses two structural inefficiencies in quantum-sampling-based diagonalization workflows. First, we integrate the Linear Scaling CNOT UCCSD (LCNot-UCCSD) ansatz into the QSCI framework, replacing the O(N6)\mathcal{O}(N^6) CCSD parameter initialization of the competing LUCJ ansatz approach with O(N4)\mathcal{O}(N^4) MP2-amplitude initialization. Second, we introduce QSCI-RBM, a variant that replaces the configuration recovery of the SQD framework with a Restricted Boltzmann Machine (RBM) acting as a compact generative subspace expansion model. Both are evaluated on eight different molecules in STO-3G across 14 controlled artificial error levels with 100 independent runs each, validated on potential energy surface scans of the N2_2 molecule in cc-pVDZ, and embedded within DMET to treat the FDA-approved antiviral Amantadine (C10_{10}H17_{17}N, 11 DMET fragments) and the active region of the SARS-CoV-2 main protease complexed with its covalent inhibitor Carmofur (PDB: 7BUY, C15_{15}H28_{28}N4_4O5_5S, 10 fragments). To our knowledge, this is the first deployment of LCNot-UCCSD within QSCI on a quantum computing simulator, and the first DMET-QSCI(LCNot-UCCSD)-RBM application to an industry-relevant protein-ligand system. By utilizing a fraction of the classical computing resources required by the current state-of-the-art work by Cleveland Clinic, RIKEN, and IBM Quantum, this approach enables more efficient and economical drug discovery simulations for the industry.
Mar 31, 2026

Perspective: Towards sustainable exploration of chemical spaces with machine learning

Artificial intelligence is transforming molecular and materials science, but its growing computational and data demands raise critical sustainability challenges. In this Perspective, we examine resource considerations across the AI-driven discovery pipeline--from quantum-mechanical (QM) data generation and model training to automated, self-driving research workflows--building on discussions from the ``SusML workshop: Towards sustainable exploration of chemical spaces with machine learning'' held in Dresden, Germany. In this context, the availability of large quantum datasets has enabled rigorous benchmarking and rapid methodological progress, while also incurring substantial energy and infrastructure costs. We highlight emerging strategies to enhance efficiency, including general-purpose machine learning (ML) models, multi-fidelity approaches, model distillation, and active learning. Moreover, incorporating physics-based constraints within hierarchical workflows, where fast ML surrogates are applied broadly and high-accuracy QM methods are used selectively, can further optimize resource use without compromising reliability. Equally important is bridging the gap between idealized computational predictions and real-world conditions by accounting for synthesizability and multi-objective design criteria, which is essential for practical impact. Finally, we argue that sustainable progress will rely on open data and models, reusable workflows, and domain-specific AI systems that maximize scientific value per unit of computation, enabling efficient and responsible discovery of technological materials and therapeutics.